PharmAla Biotech is a Canadian biotechnology company dedicated to the domestic research, development, and manufacturing of clinical-grade MDMA and novel MDXX compounds. The company focuses on alleviating the global shortage of clinical-grade MDMA to facilitate scientific research and clinical trials. PharmAla has established North America's first cGMP MDMA value chain, encompassing the manufacturing of Active Pharmaceutical Ingredient (API) and drug product formulation. Additionally, the company is engaged in preclinical research on patented Novel Chemical Entities (NCEs) based on MDXX class molecules, aiming to improve their safety profiles for therapeutic use. Committed to regulatory excellence, PharmAla collaborates with licensed laboratories to ensure compliance and quality in all its processes.